The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. This Boehringer Ingelheim (BI) & Lilly Alliance webpage is hosted on GPnotebook on behalf of the BI & Lilly Alliance. GPnotebook is published by Oxbridge Solutions Ltd®, a subsidiary of OmniaMed Communications Ltd. Diabetesonthenet is published by OmniaMed Communications Ltd. Copyright 2023 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim about BI’s products, services and events.
NP-GB-103570 | April 2023
You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim about BI’s products, services and events.
NP-GB-103570 | April 2023
You are leaving GP Notebook
This link will take you to a third party website. GP Notebook does not control or endorse this third party website and is not responsible for its content or privacy policy
You are leaving GP Notebook
This link will take you to a third party website. GP Notebook does not control or endorse this third party website and is not responsible for its content or privacy policy
Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:
Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for peoplefrom South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
Reference: 10. © NICE 2023 Tirzepatide for treating type 2 diabetes. Available from https://www.nice.org.uk/
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.